Home › Trials › NCT05703971

Combination therapy for extensive stage small cell lung cancer

A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Phase1; Phase2 Interventional Genprex, Inc. · NCT05703971

This study is testing a new combination treatment for patients with extensive stage small cell lung cancer who have responded to their initial therapy to see if it helps them stay healthy longer.

Quick facts

PhasePhase1; Phase2
Study typeInterventional
Enrollment62 (estimated)
Ages18 Years and up
SexAll
SponsorGenprex, Inc. Industry-sponsored
Drugs / interventionsatezolizumab, radiation
Locations17 sites (Lone Tree, Colorado and 16 other locations)
Trial IDNCT05703971 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the use of quaratusugene ozeplasmid in combination with atezolizumab as maintenance therapy for patients with extensive stage small cell lung cancer (ES-SCLC) who have shown a response to initial treatment. The study consists of two phases: Phase 1 focuses on dose selection, while Phase 2 assesses the safety and efficacy of the recommended dose. Patients must have completed at least three cycles of initial therapy without tumor progression to qualify for this trial. Toxicities will be monitored using established criteria to ensure patient safety throughout the study.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with confirmed ES-SCLC who have responded to initial treatment with carboplatin, etoposide, and atezolizumab.

Not a fit: Patients with significant comorbidities, uncontrolled brain metastases, or those who have not responded to initial therapy may not benefit from this study.

Why it matters

Potential benefit: If successful, this therapy could improve outcomes for patients with extensive stage small cell lung cancer by providing effective maintenance treatment.

How similar studies have performed: Other studies have shown promising results with similar combination therapies in small cell lung cancer, indicating potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Male or female aged ≥18 years.
* Documented history of histologically or cytologically confirmed ES-SCLC, prior to starting treatment with the combination of atezolizumab, carboplatin, and etoposide
* Complete Response (CR), Partial Response (PR), or Stable Disease (SD) after receiving at least three cycles, and no more than four cycles, of atezolizumab, carboplatin, and etoposide.
* Eastern Cooperative Oncology Group performance status (ECOG PS) score from 0 to 1.
* Must be ≥28 days beyond major surgical procedures such as thoracotomy, laparotomy, or joint replacement, and must not have evidence of wound dehiscence, active wound infection, or comparable major residual complications of the surgery per Investigator assessment.
* Asymptomatic brain metastases must meet ALL criteria of the following (a-d):

  1. No history of seizures in the preceding six months.
  2. Definitive treatment must be completed ≥21 days prior to enrollment.
  3. Must be off steroids administered because of brain metastases or related symptoms for ≥7 days.
  4. If had previous brain irradiation, post-treatment imaging must demonstrate stability or regression of the brain metastases.
* Absolute neutrophil count (ANC) \>1500/mm3, platelet count \>100,000/mm3 within ≤28 days.
* Adequate renal function documented by serum creatinine of ≤1.5 mg/dL or calculated creatinine clearance \>50 ml/min within ≤28 days.
* Adequate hepatic function as documented by serum bilirubin \<1.5 mg/dL and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 X upper limit of normal (ULN) within ≤28 days.
* Stable cardiac condition with a left ventricular ejection fraction ≥40% within ≤28 days.
* If female of childbearing potential (FOCBP), must have negative serum pregnancy test (serum beta-human chorionic gonadotropin \[β-hCG\]) within ≤7 days of first dose.
* FOCBP and non-sterile men who are sexually active with FOCBP must agree to use two forms of contraception including one highly effective and one effective methods beginning ≥2 weeks prior to enrollment through for four months following the last dose of study treatment.
* If male, must agree to no sperm donation during study treatment and for an additional four months following the last dose of study treatment.
* Must have voluntarily signed an informed consent in accordance with institutional policies.

Exclusion Criteria:

* Unable to tolerate atezolizumab treatment, leading to early treatment discontinuation or prolonged/frequent dosage modifications in previous atezolizumab treatment as determined by the Investigator.
* Received prior gene therapy.
* Received prophylactic cranial irradiation or consolidation thoracic radiation.
* Active systemic viral, bacterial, or fungal infection(s) requiring treatment.
* Serious concurrent illness or psychological, familial, sociological, geographical, or other concomitant conditions that, in the opinion of the Investigator, would not permit adequate follow-up and compliance with the study protocol.
* History of autoimmune disease requiring immunosuppression.
* History of myocardial infarction or unstable angina within ≤6 months.
* Known human immunodeficiency virus (HIV) infection or has active hepatitis infection.
* Female who is pregnant or breastfeeding

Where this trial is running

Lone Tree, Colorado and 16 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Small Cell Lung Cancer Extensive Stageatezolizumabatezolizumab and hyaluronidase-tqjsTumor Suppressor Gene 2Lipid NanoparticleGene TherapyTECENTRIQES-SCLC
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.